TriangleFOR PATIENTS · SOURCE READING
Treatment of recurrent or refractory Burkitt lymphoma
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 9, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.
Context: Treatment Options for Childhood Non-Hodgkin Lymphoma / Burkitt lymphoma
For information about the treatments listed below, see Treatment Option Overview.
Source links and citations
Treatment of recurrent or refractory Burkitt lymphoma may include:
Source links and citations
combination chemotherapy with or without targeted therapy (rituximab)
Source links and citations
targeted therapy (rituximab), combination chemotherapy, and dexamethasone
Source links and citations
high-dose chemotherapy with stem cell transplant with the patient's own cells or cells from a donor
Source links and citations
CAR T-cell therapy
Source links and citations
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Source links and citations
Preserved source evidence · Independent clinical review pending · Not medical advice